Actinogen Medical is a biotechnology company developing innovative treatments for neurological diseases associated with dysregulated brain cortisol. The company is currently developing its lead compound, Xanamem, as a new therapy for Alzheimer’s disease (AD), Major Depressive Disorder, Fragile X Syndrome, and other neurological diseases where reducing cortisol inside brain cells could have a positive impact. Positive results for its Phase I/II XanaMIA Part A trial were recently announced. The double-blind, placebo controlled, dose ranging study evaluated Xanamem in 107 healthy elderly people aged 50-80 years. Findings showed the drug’s ability to rapidly enhance attention and working memory. In addition, Xanamem was safe and well-tolerated.
On 14 June, Actinogen Medical announced that it has finalised the designs for its planned Phase II trials in AD and Major Depressive Disorder. The AD XanaMIA Part B Phase II trial will be a six-month dose-ranging, placebo-controlled trial in approximately 300 people with early stages of AD, including people with Mild Cognitive Impairment (MCI) as well as people with mild AD. Outcomes will be measured by the Cogstate Cognitive Test Battery (CTB) used in the recent XanaMIA Part A trial, supplemented by a variety of other tests of memory, attention and executive function. Results are expected in 2024. https://www.globenewswire.com/news-release/2022/06/14/2462043/0/en/Actinogen-Announces-Phase-2-Trials-in-Alzheimer-s-Disease-and-Depression.html